Baxter International Faces Class Action Over Novum LVP Safety Concerns
- Baxter International faces a class action lawsuit for allegedly misleading shareholders about safety issues with its Novum LVP product.
- The Novum LVP has reportedly experienced serious malfunctions, posing significant risks to patient safety and healthcare operations.
- Ongoing legal challenges could severely impact Baxter's credibility, customer trust, and overall reputation in the healthcare market.
Baxter International Faces Class Action Over Alleged Safety Issues with Novum LVP Product
Baxter International, Inc. is currently embroiled in potential legal turmoil as the Gross Law Firm announces a class action lawsuit against the company. The lawsuit targets shareholders who purchased Baxter shares between February 23, 2022, and July 30, 2025, urging them to consider becoming lead plaintiffs. Central to the allegations are claims that Baxter made false or misleading statements regarding its Novum LVP (Large Volume Pump) product, which has reportedly experienced systemic defects leading to critical malfunctions. These malfunctions include underinfusion, overinfusion, and complete non-delivery of fluids, all of which pose substantial risks to patient safety, including the possibility of serious injury or death.
The allegations assert that Baxter had knowledge of multiple malfunctions and associated injuries or fatalities but failed to adequately address these issues, which resulted in insufficient alerts to customers. This situation raises significant concerns about the safety of the Novum LVPs, prompting fears that healthcare providers may need to withdraw existing units from service and halt new sales. Consequently, the company's representations regarding the safety, efficacy, and market potential of the Novum LVPs are called into question. The Gross Law Firm emphasizes that shareholders interested in participating in the class action must register before the December 15, 2025, deadline to seek lead plaintiff status.
As the legal proceedings unfold, the implications for Baxter International could be far-reaching. The company’s credibility and its ability to maintain customer trust in its products hang in the balance. Furthermore, the ongoing concerns surrounding the Novum LVPs underscore broader issues in the medical device industry regarding product safety and transparency. Stakeholders will be closely monitoring the developments as Baxter navigates this challenging situation, which could significantly impact its operations and reputation in the healthcare market.
In a separate but relevant development, Inlyte Energy has announced the formation of an Advisory Board, including former FERC Chairman Jon Wellinghoff and other energy sector notables. This strategic move aims to bolster Inlyte's position in the growing energy storage market. Meanwhile, Baxter's legal challenges highlight the critical need for transparency and accountability in the medical device sector, reinforcing the importance of rigorous safety standards in healthcare products.
Related Cashu News

Merit Medical Systems Launches Employee Stock Ownership Plan to Boost Engagement and Stability
Merit Medical Systems (Ticker: MMSI) recently takes a significant step in enhancing its employee engagement and ownership structure with the launch of a new Employee Stock Ownership Plan (ESOP). The c…

Brookdale Senior Living launches second season of educational podcast "The Grey Take.
Brookdale Senior Living (Ticker: BKD) launches the second season of its popular podcast, "The Grey Take," which serves as a valuable resource for families exploring senior living options. The podcast…

Molina Healthcare Gains Momentum with Increased Risk Adjustment Payments and Positive Revenue Outlook
Molina Healthcare (Ticker: MOH) is making significant strides in its revenue outlook due to recently released risk adjustment figures from the Centers for Medicare & Medicaid Services (CMS). These upd…

Align Technology Faces Antitrust Investigation by European Commission Over Competitive Practices
Align Technology Inc. (Ticker: ALGN) faces a formal antitrust investigation from the European Commission, marking a significant development in the medical devices sector. This inquiry arises from a co…

